Home
Scholarly Works
Bleeding risk of glycoprotein (GP) IIB IIIA...
Conference

Bleeding risk of glycoprotein (GP) IIB IIIA inhibitors or thienopyridines with fondaparinux vs enoxaparin in acute coronary syndromes: Insights from the oasis 5 trial

Authors

Jolly SS; Afzal R; Theroux P; Fung A; Chrolavicius S; Yusuf S; Mehta SR

Volume

23

Pagination

pp. 223C-223C

Publisher

PULSUS GROUP INC

Publication Date

October 1, 2007

Conference proceedings

CANADIAN JOURNAL OF CARDIOLOGY

ISSN

0828-282X

Labels

Contact the Experts team